Over 1000 studies available in EU register of approved drugs
The 1,000th study has been uploaded to the European Union (EU) electronic Register of Post-Authorisation Studies (EU PAS Register), a significant landmark in the transparency initiative.
The 1,000th study has been uploaded to the European Union (EU) electronic Register of Post-Authorisation Studies (EU PAS Register), a significant landmark in the transparency initiative.
Double-hit lymphoma has a poor prognosis and the best option for patients could be positive identification and treatment with novel agents, but there are arguments for and against… read more.
Chronic, cancer-related fatigue (CRF) is associated with a sudden- onset, profound lack of energy that is not relieved by rest. It is different from the fatigue experienced by… read more.
Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.
Maintenance therapy with lenalidomide can improve PFS in patients with newly-diagnosed MM by almost two years compared with observation alone, in patients of all ages and all risk… read more.
Dr Peter Irving (London) talks about one of the hot topics for the future -Maximising the bang for your buck in IBD. He highlights the possible benefits of treating… read more.
Commentary and insights from Dr Filip Baert, (Roeselare, Belgium) and Usha Chauhan (McMaster University, Canada)
High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.
Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…
If you missed ECCO this year, or if you attended, but didn’t get to see everything you’d hoped to, listen to the key highlights from Professor Séverine Vermeire… read more.
An interesting session at ECCO dealt with the patients for whom there is sparce data to guide their treatment – experts in the field gave their guidance to… read more.
Never before in the history of IBD have there been so many promising compounds in the pipeline. In a scientific session dedicated to new compounds, leading investigators discussed… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.